Thank you, Mr. Chair.
Thank you to all our witnesses here today. I appreciate all your presentations.
I'm going to go first to Mr. Prowten with the Juvenile Diabetes Research Foundation.
Just to be clear, this was a folio change, where CRA updated its interpretation of who can use the disability tax credit in regard to life-sustaining treatment. Is that correct?